NCT00350545View on ClinicalTrials.gov

A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease

NACompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

May 31, 2012

Study Completion Date

October 31, 2014

Conditions
Graft vs Host Disease
Interventions
DRUG

Rituximab

375 mg/m2;IV infusion once weekly for four doses (days 1,8,15,22); option for second 4-week course at week 9

DRUG

Prednisone

1 mg/kg; po per day with taper

DRUG

Cyclosporine A

trough 200-300 or lower; po

DRUG

tacrolimus

trough 5-10 or lower; po

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

All Listed Sponsors
lead

Stanford University

OTHER

NCT00350545 - A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease | Biotech Hunter | Biotech Hunter